BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Rating Cut to “Hold” at Wall Street Zen

Wall Street Zen lowered shares of BioMarin Pharmaceutical (NASDAQ:BMRN) from a buy rating to a hold rating in a research note released on Saturday,Wall Street Zen reports.

Several other equities research analysts also recently commented on the stock. HC Wainwright restated a “neutral” rating and issued a $60.00 price target on shares of BioMarin Pharmaceutical in a research report on Thursday, September 10th. Weiss Ratings cut shares of BioMarin Pharmaceutical from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, September 18th. Morgan Stanley cut their target price on shares of BioMarin Pharmaceutical from $124.00 to $122.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 21st. Canaccord Genuity Group boosted their target price on shares of BioMarin Pharmaceutical from $111.00 to $114.00 and gave the company a “buy” rating in a research note on Monday, August 10th. Finally, Oppenheimer increased their target price on BioMarin Pharmaceutical from $95.00 to $97.00 and gave the company an “outperform” rating in a report on Friday, August 7th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, BioMarin Pharmaceutical presently has an average rating of “Moderate Buy” and an average price target of $88.38.

BioMarin Pharmaceutical Trading Up 1.8%

Shares of BMRN opened at $58.51 on Friday. The business’s 50-day moving average price is $60.62 and its 200 day moving average price is $58.44. The company has a current ratio of 2.39, a quick ratio of 1.32 and a debt-to-equity ratio of 0.56. The stock has a market capitalization of $11.33 billion, a P/E ratio of 158.14, a P/E/G ratio of 0.64 and a beta of 0.22. BioMarin Pharmaceutical has a 1-year low of $49.26 and a 1-year high of $70.98.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating analysts’ consensus estimates of $0.95 by $0.25. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. The company had revenue of $989.71 million during the quarter, compared to analyst estimates of $932.03 million. During the same period in the prior year, the firm earned $1.44 earnings per share. The business’s quarterly revenue was up 20.0% on a year-over-year basis. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Analysts expect that BioMarin Pharmaceutical will post 2.59 earnings per share for the current year.

Institutional Trading of BioMarin Pharmaceutical

Hedge funds have recently made changes to their positions in the stock. Bfsg LLC acquired a new position in BioMarin Pharmaceutical in the third quarter worth approximately $1,052,000. Oregon Public Employees Retirement Fund lifted its stake in BioMarin Pharmaceutical by 0.5% in the third quarter. Oregon Public Employees Retirement Fund now owns 40,117 shares of the biotechnology company’s stock valued at $2,407,000 after acquiring an additional 200 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in BioMarin Pharmaceutical in the third quarter valued at approximately $186,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in BioMarin Pharmaceutical in the third quarter valued at approximately $705,000. Finally, Profund Advisors LLC grew its position in BioMarin Pharmaceutical by 34.3% in the third quarter. Profund Advisors LLC now owns 37,548 shares of the biotechnology company’s stock worth $2,253,000 after acquiring an additional 9,582 shares in the last quarter. 98.71% of the stock is owned by hedge funds and other institutional investors.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company’s research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin’s marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.